$BRTX News

Maxim Group Downgrades BioRestorative Therapies to Hold

BioRestorative Therapies Announces Reverse Stock Split

BioRestorative Therapies Announces 1-For-20 Reverse Stock Split

Biorestorative Therapies Suspends All Orders, Shipments Of ExoCR, BioX Biocosmeceutical Product Lines Effective Immediately, On Aug 7; Conducting Review Of The Documentation, Sourcing, Regulatory Status Associated With Suspended Products; Has Not Made Decision To Discontinue Suspended Product Lines

BioRestorative Therapies Says Lance Alstodt Resigns As President, CEO, Chairman And All Other Positions Effective July 13, 2026; Robert Kristal Resigns As CFO And All Other Positions; Katharyn Field Appointed As CEO, President, And Interim CFO

BioRestorative Therapies Announces Completion of BRTX-100 Phase 2 Manufacturing, Highlighting Integrated Regenerative Biologics Platform

BioRestorative Therapies Completes Production For Its BRTX-100 Phase 2 Clinical Study To Support Current Clinical Development To Treat Chronic Lumbar Disc Disease

BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX)

Kaos Capital Acquires 4.9% Of Issued And Outstanding Common Stock Of BioRestorative Therapies; Terms Undisclosed

BioRestorative Completes Phase 2 Dosing of BRTX-100, Advancing Lead Regenerative Spine Program Toward 2027 Topline Data

BioRestorative Therapies Doses Last Participant In Its Phase 2 Clinical Study Of BRTX-100 To Treat Chronic Lumbar Disc Disease

What Makes Biorestorative Therapies (BRTX) a New Buy Stock

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Misses Revenue Estimates

BioRestorative Therapies Presents New Preclinical Data at ISCT 2026 Highlighting Source-Specific Exosome Functionality and Commercial Applications in BioCosmeceuticals

BioRestorative Therapies Presents Data Showing MSC-Derived Exosomes Have Source-Specific Functional Signatures For Targeted Therapeutic Applications At The International Society For Cell & Gene Therapy 2026 Annual Meeting

BioRestorative Therapies Reports Expanded Phase 2 Blinded Dataset for BRTX-100 Showing Sustained Pain and Functional Improvements in Chronic Lumbar Disc Disease

BioRestorative Therapies Reports 52% Of Phase 2 Patients Achieve At Least 50% Pain And Function Improvement At 52 Weeks With No Dose-Limiting Toxicity In ISCT 2026 Update

BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform